Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate-autologous tumor derived microparticles
- Development stage
- Unknown
- Lead developer
- Union Hospital of Huazhong University of Science and Technology
- Modality
- Small Molecules, Cell Therapies, Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
MTX-ATMPs are a novel therapeutic modality consisting of the chemotherapeutic agent methotrexate (MTX) packaged within autologous tumor-derived microparticles (ATMPs). Developed by researchers at Union Hospital, Tongji Medical College, this approach utilizes the microparticles as a delivery vehicle that tumor cells naturally internalize via endocytosis. This mechanism allows the drug to bypass common resistance pathways, such as drug efflux pumps, and specifically target tumor-repopulating cells (TRCs). Once inside the malignant cell, the methotrexate is released to inhibit dihydrofolate reductase, leading to the disruption of DNA synthesis and subsequent cell death. The therapy is primarily investigated for the treatment of malignant pleural effusion (MPE), where it is administered intrapleurally to clear malignant cells and potentially stimulate a localized anti-tumor immune response.
- Other names
- methotrexate-loaded tumor-derived microparticlesMTX-ATMP
02
Targets
Nucleotide synth (Nucleotide synthesis enzymes)
Beyond the preview
Go deeper on methotrexate-autologous tumor derived microparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate-autologous tumor derived microparticles.